Zurko Research, Spanish CRO with more than 16 years of experience in the evaluation of cosmetics and medical devices/OTC, is pleased to announce a significant milestone in its business history. The company has acquired, last September, the majority (70%) of shares of the group company Proteos Biotech SL; further strengthening its position as a leader in the national and international sector.
This operation marks an outstanding moment for Zurko Research, since it not only regains control over the successful Proteos Biotech, it has also granted entry into its remaining shareholding to Tresmares Capital Group, a leading investment platform in Spain that has the support of Banco Santander; which guarantees a solid base and a strategic focus on its continued growth. The transaction was carried out by leading and expert advisors such as Garrigues, Evergreen Legal and Deloitte Financial Advisory.
The increase in Zurko Research’s share ownership is a testament to the company’s commitment to supporting and growing business projects based on quality, safety and excellence, such as the company Proteos Biotech and the other recent acquisition (March 2023) of the CTC Hair Technology Institute.
These operations allow Zurko Research to maintain its investment independence and continue to explore opportunities for growth and economic development.
The entire Zurko Research team is enthusiastically facing this new stage with the support of an increasingly solid and promising group.
To quote Henry Ford: “Arriving together is the beginning. Staying together is progress. Working together is success.”
